CELL INTELLIGENCE · 肿瘤细胞治疗研究

OBJECTIVES: Intravesical instillation of bacillus Calmette-Guérin (BCG) is the standard treatment for bladder carcinoma in situ (CIS); however, factors that predict its therapeutic efficacy have not been identified. We focused on immune cells infiltrating within 20 μm of tumor cells and examined factors that predict the efficacy of intravesical BCG treatment. METHODS: Formalin-fixed, paraffin-embedded tissue specimens from 82 patients with bladder CIS treated with intravesical BCG were used. Patients who relapsed after BCG treatment were grouped as non-responders, and those who did not were grouped as responders. Tissue sections were immunostained for CD4, CD8, and forkhead box P3 (FOXP3), a marker of regulatory T cells (Tregs). The number of immune cells positive for the above markers present within 20 μm of the lower edge of the basement membrane on which CIS is present was counted and compared between groups. RESULTS: Both the peritumoral Treg density and Treg+/CD4+ cell ratio were significantly greater in nonresponders than in responders. The patients were divided into high and low groups based on Treg density and Treg+/CD4+ cell ratio cut-off values; recurrence-free survival was significantly longer in the low group than in the high group (p = 0.005 and p < 0.001, respectively). CONCLUSIONS: The Treg density and Treg+/CD4+ cell ratio within 20 μm of bladder CIS may be useful predictors of therapeutic response to BCG.